satralizumab
SpainDrugs containing this active substance
-
It is used to treat neuromyelitis optica spectrum disorder (NMOSD) in adults and adolescents aged 12 years and older. This disease affects the optic nerves and the spinal cord due to a malfunction of the immune system.
Form: solution for injection in a pre-filled syringe
Active substance Dosage satralizumab 120 mg Manufacturer: Roche Registration Gmbh